IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Aptus Pharma IPO is a Book Building listing on BSE SME exchange, with an ipo size of ₹ [●] Cr. The company is based in Ahmedabad and caters to Pharmaceutical sector. Interactive Financial Services is the merchant banker of Aptus Pharma IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 18th June 2025.
Aptus Pharma IPO posted revenues of ₹ 24.55 crores and PAT of ₹ 3.09 crores in FY25 on annualised basis.
Revenue:
₹ 24.55 Cr.
EBITDA Margin:
19.35
% 
Net Worth: ₹ 6.96 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 1.08 times
Financial results of Aptus Pharma IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY25 | FY24 | FY23 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 21.91 | 10.02 | 6.22 | ||
| Net Worth | 6.96 | 1.77 | 0.97 | ||
| Total Debt | 10.35 | 5.31 | 2.21 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
24.55 | 17.85 | 13.89 | ||
EBITDA
EBITDA on annualised basis |
4.75 | 1.49 | 0.58 | ||
PAT
PAT on annualised basis |
3.09 | 0.79 | 0.19 | ||
Aptus Pharma IPO PAT Margin is 12.59 % , ROCE (Return on Capital Employed) is 45.66 % as per latest financial. The below table shows Aptus Pharma IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY25 | FY24 | FY23 |
|---|---|---|---|
| EBITDA Margin (%) | 19.35 | 8.35 | 4.18 |
| PAT Margin (%) | 12.59 | 4.43 | 1.37 |
| EPS (₹) | 6.37 | 5.32 | 1.30 |
| ROE (%) | 44.40 | 44.63 | 19.59 |
| ROCE (%) | 45.66 | 21.70 | 12.77 |
| ROA (%) | 14.10 | 7.88 | 3.05 |
| Debt to Equity | 1.49 | 3.00 | 2.28 |
The market Capitalisation of Aptus Pharma IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Aptus Pharma IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Aptus Pharma IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Aptus Pharma IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Aptus Pharma IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Aptus Pharma IPO reported revenue of ₹ 24.55 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Aptus Pharma IPO provide insights into sales growth, market demand, and business scalability.
Aptus Pharma recorded an EBITDA of ₹ 4.75 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Aptus Pharma Profit After Tax (PAT) is ₹ 3.09 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 24.55 Cr.
EBITDA Margin:
19.35
%
Net Worth: ₹ 6.96 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 1.08 times
Aptus Pharma operates in Pharmaceutical and Marketing, And Distribution Of Finished Pharmaceutical Formulations. The Issue is listed on BSE SME in Jun, 2025. Aptus Pharma IPO size was with Issue price of .
Merchant Banker(s) of Aptus Pharma IPO: Interactive Financial Services Limited
Aptus Pharma IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Aptus Pharma IPO listed at a listing price of against the offer price of .
The current market price of Aptus Pharma is .
Why Us?
